antalarmin

Antalarmin is a **non-peptide small molecule drug** that acts as a selective antagonist of the **corticotropin-releasing hormone receptor 1 (CRH1, also called CRF1)**[3][1]. By blocking CRH1, antalarmin **reduces the release of adrenocorticotropic hormone (ACTH)** in response to chronic stress, potentially moderating the effects of excessive glucocorticoids and negative stress-related physiological and behavioral outcomes[1][3]. It has been investigated in preclinical and early clinical studies for stress-related psychiatric disorders (e.g., anxiety, depression), stress-induced hypertension, inflammatory conditions such as arthritis, gastrointestinal disorders like irritable bowel syndrome, and substance use disorders[1][4][5][3]. Despite promising preclinical data, clinical development has not progressed to advanced phases nor regulatory approval[4][6].